Climb Bio, Inc.

NASDAQ:CLYM

Biotechnology

Healthcare
$9.78 +0.17%

+$0.02 today

Market cap
$574.46M
Beta
0.10
P/E (TTM)
-14.7
EPS (TTM)
-$0.77
52W Low $1.17High $12.48

Volume 0.59M

Average 0.88M

Returns on capital

Climb Bio, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-37.3%

avg -42.3%

ROIC

-42.2%

avg -43.9%

ROA

-35.7%

avg -39.6%

Analysis

ROA is currently the strongest return metric at -35.7% versus its period average of -39.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Aoife Brennan BCh MMSc

Chief Executive Officer, President & DirectorUSD 1.09M50——

Perrin Wilson

Chief Business OfficerUSD 793.42K47——

Susan Altschuller

CFO & Principal Accounting OfficerUSD 570.81K44142.50K0.21%

Edgar D. Charles

Chief Medical Officer————

Adam Villa

Senior Vice President of Technical Operations————

Chandra Adams

Senior VP, General Counsel & Secretary————

Ashley Jones

Senior Vice President of People & Workforce Strategy————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

3

$779,625.64

Sells

6

$2.65M

Net Transaction Value

−$1.87M

Net selling

Most Active

Thomas Stephen Basil

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 15, 26

Thomas Stephen Basil

Direct

Sell$1.4M
Jun 29, 26

Brennan Aoife

Direct

Sell$407K
Feb 26, 26

Thomas Stephen Basil

Direct

Sell$114.3K
Feb 25, 26

Thomas Stephen Basil

Direct

Sell$236K
Feb 13, 26

Thomas Stephen Basil

Direct

Sell$58.1K
Feb 12, 26

Thomas Stephen Basil

Direct

Sell$471K
Jan 5, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Buy$24.9K
Dec 12, 25

RA CAPITAL MANAGEMENT, L.P.

Indirect

Buy$290.2K
Dec 11, 25

RA CAPITAL MANAGEMENT, L.P.

Indirect

Buy$464.6K

Summary

Insiders reported 3 buys worth $779,625.64 and 6 sells worth $2.65M over the last 12 months. That adds up to net selling of $1.87M. Thomas Stephen Basil was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Climb Bio, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CLYM's management, answered from reported figures.

Who manages CLYM?

Climb Bio, Inc. (CLYM) lists 7 active executives. The top listed executive is Aoife Brennan BCh MMSc, Chief Executive Officer, President & Director.

Are CLYM insiders buying or selling?

Recent insider activity shows net buying of $13.21M.